Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 16, 2022BiomedicinesOpen Access

Therapeutic Potential of Glucagon-like Peptide-1 Agonists in Polycystic Ovary Syndrome: From Current Clinical Evidence to Future Perspectives

View Full Paper
Ask AI
Bookmark
Share

Authors

MJMojca JensterleUniversity of LjubljanaRHRok HermanUniversity of LjubljanaAJAndrej JanežAlbert Einstein College of Medicine

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Jensterle et al. (2022) studied this question.

synapsesocial.com/papers/6a71361835aa2c282ce284b2https://doi.org/10.3390/biomedicines10081989
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Update on the effects of GLP-1 receptor agonists for the treatment of polycystic ovary syndrome2021 · 80 citations
  2. 2Polycystic ovary syndrome (PCOS) and the risk of coronary heart disease (CHD): a meta-analysis2016 · 184 citations
  3. 3The therapeutic effects of glucagon-like peptide-1 receptor agonists and metformin on polycystic ovary syndrome2021 · 32 citations
  4. 4Short-term effectiveness of low dose liraglutide in combination with metformin versus high dose liraglutide alone in treatment of obese PCOS: randomized trial2017 · 92 citations
  5. 5Short-term combined treatment with exenatide and metformin for overweight/obese women with polycystic ovary syndrome2021 · 62 citations